A PYMNTS Company

Japan/Israel: Pharma rivals call truce in generic drug patent collusion case

By  |  February 19, 2014

Pharmaceutical rivals Ranbaxy and Teva have reportedly decided to settle litigation that accused the companies of colluding on the sale of generic drugs, according to New York Attorney General Eric Schneiderman.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    In a statement, Schneiderman announced that Japan’s Daiichi Sankyo, which owns Ranbaxy, and Israel-based Teva conspired to agree not to challenge each other’s generic drug sales for a period of six months after the brand name patent expires. Reports say that agreement affected the sale of the generic form of the world’s top-selling drug Lipitor.

    The Attorney General said that “agreements between drug manufacturers to protect each other’s market positions violate principles of antitrust law, and can lead to higher drug prices.”

    The companies reportedly made a “no challenge” agreement with each other in 2010 to not challenge each other’s filings for the exclusive right of the generic forms of pharmaceuticals.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.